Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Alzheimer’s Disease Diagnostics Market: By Diagnostic Techniques, By Type, By End Use, and Region Forecast 2020-2031
Alzheimer’s Disease Diagnostics Market size was valued at US$ 5.2 billion in 2024 and is projected to reach US$ 9.1 billion by 2031, growing at an 8.1% from 2025–2031. Moreover, the U.S. Alzheimer’s Diagnostics Market is projected to grow significantly, reaching an estimated value of US$ 3,600 million (US$ 3.6 billion) by 2031.
The market is poised at the intersection of clinical demand and technological advancement. With the world's population growing older, early and precise diagnosis of Alzheimer's disease is becoming an imperative rather than a decision. Diagnosis has moved beyond clinical observation to utilizing sophisticated tools such as PET imaging, cerebrospinal fluid biomarkers, and AI-based cognitive tests. What was once a slow and uncertain process is being re-scripted by precision medicine, making intervention on time and better-informed care planning possible. This shift is not merely technical it's deeply human. It's a move away from reactive care and toward proactive understanding, giving people and families a longer window of time to adapt, respond, and live with dignity.
The course of this sector appears to be one of increased cooperation between pharma, diagnostic companies, and tech entrepreneurs looking for non-invasive, scalable, and affordable diagnostic machines. Liquid biopsies and panels of blood-based biomarkers—formerly in the realm of experimentation—are now moving to clinical trials with real-world applications. Regulators are beginning to move faster to approve new test platforms, and even payers are demonstrating early signs of coverage for pre-symptomatic testing. These advancements aren't only shaping the market; they're upsetting the conventional care continuum. As early-stage detection becomes the norm and not the exception, Alzheimer's diagnosis is transforming from a specialist research issue to an integral component of neurological care systems globally.
Based on the Diagnostics Technique
Among the new diagnostic tools, blood-based biomarkers are revolutionizing the affordability and availability of Alzheimer's testing. Unlike cerebrospinal fluid sampling or imaging, these tests draw from easily accessible blood samples to measure first pathological changes e.g., beta-amyloid and phosphorylated tau levels with the result of being able to screen on a routine basis even in non-specialist centers. Their very minimally invasive character eliminates the psychological and logistical hurdles commonly linked to conventional diagnostics. In addition, their scalability matches the growing focus on early population-level screening. Laboratories and firms are competing to bring these tests to market, aided by favourable trial outcomes and regulatory fast-track mechanisms. With precision medicine development, diagnostics based on blood will be the foundation of Alzheimer's risk assessment and disease surveillance.
Based on the type
The diagnostic segment commands the Alzheimer's diagnostics market based on clinical demand for precise, stage-specific diagnosis of the disease. Unlike screening or triage, which is initial, diagnostic devices affirm the presence and progression of Alzheimer's through a combination of imaging, mental status examination, and biomarker testing. Hospitals and specialty clinics utilize this level to create patient-specific treatment plans, address comorbidities, and trigger proper caregiver planning. The arrival of novel therapeutics and disease-altering drugs has placed precise diagnosis in the spotlight. Payors and regulatory bodies are ever more making coverage decisions based on confirmed diagnostic markers, even more positioning this segment as the cornerstone to the entire diagnostic process.
Based on the end user
Hospitals represent the most important end-use environment for diagnosing Alzheimer's, in large part because they contain the entire array of test technology—MRI, PET, blood tests, and neuropsychology staff—all under one roof. Multidisciplinary geriatrics and neuroscience teams will be in a better position to unravel difficult results and orchestrate what comes next. For most patients, hospitals also are the initial point of contact after cognitive decline, putting them at the front of timely care. Also, hospital funding and teaching affiliations enable the hospitals to be involved in clinical trials for new diagnostic technology, and they become privy to innovative solutions ahead of the curve. As early diagnosis becomes the norm, hospitals are in a dual role: first-line caregivers and research centres for Alzheimer's diagnosis.
Study Period
2025-2031Base Year
2024CAGR
8.1%Largest Market
North-AmericaFastest Growing Market
Asia-Pacific
One of the strongest drivers of the Alzheimer's diagnostics market is the extremely high rate of growth in the incidence of dementia across the globe, especially among the elderly. When life expectancy rises, particularly in the developed and emerging nations, the risk pool for Alzheimer's grows accordingly. The World Health Organization estimates that more than 55 million individuals currently have dementia, and this number will double roughly every 20 years. This demographic condition imposes significant burden on the healthcare systems and hence early and correct diagnosis is not only a doctor's dream but a population health necessity. Governments and institutions are investing more in diagnostic facilities as it is realized that early detection halts disease progression, saves caregiver time and effort, and reduces long-term healthcare costs.
Even with great technological developments, treatment access for Alzheimer's diagnostic technology is unequal and expensive especially in low- and middle-income economies. Advanced modalities like PET imaging and cerebrospinal fluid examination are technically sophisticated, personnel-skill intensive, and laboratory intensive capital not equally distributed. Even in high-income economies, diagnosis paths may be disjointed, with patients experiencing prolonged waiting times, insurance barriers, and irregular physician referral. Moreover, stigma anxiety or emotional distress causes individuals to postpone early testing. Such innovation-access lag curbs market development, particularly on the community level as well as in preventive care. Bridging close costs and infrastructure gaps is a significant barrier to reaching equitable diagnostic coverage across the world.
Innovations in blood-based biomarker testing is one of the most promising opportunities in the diagnosis of Alzheimer's. These minimally invasive tests, that capture precise, blood-borne proteins such as beta-amyloid and phosphorylated tau, have the potential to exponentially increase access to stage-one diagnosis. In contrast to PET scans or spinal taps, blood tests can be offered in outpatient departments, even half-time in primary care facilities so they're more scalable and affordable. A number of biotech companies are far along in trials, and early results demonstrate strong correspondence with conventional diagnostic criteria. This technology has the potential to democratize the diagnosis of Alzheimer's, particularly for low-resource environments, and has the potential to change the paradigm of diagnosis from reactive neurology to proactive screening.
One of the significant trends which is shaping the Alzheimer's diagnostics landscape is the convergence of artificial intelligence (AI) into cognitive testing platforms and neuroimaging analysis. AI is increasingly being employed to identify micro patterns in speech, motion, and brain scan that may not be perceived by the human eye allowing for earlier and more precise detection of preclinical Alzheimer's. Start-ups and large tech companies are designing AI-powered platforms capable of analysing huge volumes of data from MRI, PET, and cognitive tests within seconds, cutting diagnosis time and improving precision. This is particularly fitting in remote or poorly equipped settings, where specialist access is hindered. As AI continues to develop, its implementation in diagnostics is not displacing clinicians but complementing their capacity to provide quicker, wiser, and more standardized assessments.
Report Benchmarks |
Details |
Report Study Period |
2025-2031 |
Market Size in 2024 |
US$ 5.2 billion |
Market Size in 2031 |
US$ 9.1 billion |
Market CAGR |
8.1% |
By Diagnostic Technique |
|
By Type |
|
By End User |
|
By Region |
|
According to PBI Analyst, the bacterial vaccines market is experiencing significant growth, driven by rising awareness of infectious disease prevention, government immunization programs, and advancements in vaccine technology. The increasing prevalence of antibiotic-resistant bacterial infections has further emphasized the need for effective vaccination strategies. Subunit/conjugate vaccines dominate the market due to their superior safety and immunogenicity, while paediatric vaccination remains the largest segment, supported by global immunization initiatives. Intramuscular administration is the most preferred route, ensuring optimal immune response. Hospital pharmacies lead in vaccine distribution due to their robust storage infrastructure. Continuous research, AI-driven vaccine development, and expanding immunization coverage are expected to fuel market expansion.
Download Free Sample Report
Alzheimer’s disease diagnostics market size was valued at US$ 5.2 billion in 2024 and is projected to reach US$ 9.1 billion by 2031, growing at an 8.1%.
Government-led immunization programs and increasing awareness of bacterial disease prevention are major factors driving the bacterial vaccines market.
The growing demand for combination vaccines, offering protection against multiple bacterial infections in a single dose, is shaping market expansion.
Market research is segmented based on vaccine type, patient age group, route of administration, distribution channel and region.
Asia-Pacific is the fastest-growing region due to rising healthcare investments, expanding immunization programs, and increasing vaccine production capabilities.
1.Executive Summary |
2.Global Alzheimer’s Disease Diagnostics Market Introduction |
2.1.Global Alzheimer’s Disease Diagnostics Market - Taxonomy |
2.2.Global Alzheimer’s Disease Diagnostics Market - Definitions |
2.2.1.Diagnostic Technique |
2.2.2.Type |
2.2.3.End User |
2.2.4.Region |
3.Global Alzheimer’s Disease Diagnostics Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4.Global Alzheimer’s Disease Diagnostics Market Analysis, 2020 - 2024 and Forecast 2025 - 2031 |
4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5.Global Alzheimer’s Disease Diagnostics Market By Diagnostic Technique, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
5.1. Biomarkers |
5.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Imaging Techniques |
5.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Genetic Testing |
5.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. Cognitive Assessment Tests |
5.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
6.Global Alzheimer’s Disease Diagnostics Market By Type, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
6.1. Triage |
6.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Diagnosis |
6.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Screening |
6.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
7.Global Alzheimer’s Disease Diagnostics Market By End User, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
7.1. Hospital |
7.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Diagnostic Laboratories |
7.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Academic and Research Institutes |
7.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
8.Global Alzheimer’s Disease Diagnostics Market By Region, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
8.1. North America |
8.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Europe |
8.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Asia Pacific (APAC) |
8.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
8.4. Middle East and Africa (MEA) |
8.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.4.3. Market Opportunity Analysis |
8.5. Latin America |
8.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.5.3. Market Opportunity Analysis |
9.North America Alzheimer’s Disease Diagnostics Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
9.1. Diagnostic Technique Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.1.1.Biomarkers |
9.1.2.Imaging Techniques |
9.1.3.Genetic Testing |
9.1.4.Cognitive Assessment Tests |
9.2. Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.2.1.Triage |
9.2.2.Diagnosis |
9.2.3.Screening |
9.3. End User Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.3.1.Hospital |
9.3.2.Diagnostic Laboratories |
9.3.3.Academic and Research Institutes |
9.4. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.4.1.United States of America (USA) |
9.4.2.Canada |
10.Europe Alzheimer’s Disease Diagnostics Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
10.1. Diagnostic Technique Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Biomarkers |
10.1.2.Imaging Techniques |
10.1.3.Genetic Testing |
10.1.4.Cognitive Assessment Tests |
10.2. Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.Triage |
10.2.2.Diagnosis |
10.2.3.Screening |
10.3. End User Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.Hospital |
10.3.2.Diagnostic Laboratories |
10.3.3.Academic and Research Institutes |
10.4. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.4.1.Germany |
10.4.2.France |
10.4.3.Italy |
10.4.4.United Kingdom (UK) |
10.4.5.Spain |
11.Asia Pacific (APAC) Alzheimer’s Disease Diagnostics Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
11.1. Diagnostic Technique Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Biomarkers |
11.1.2.Imaging Techniques |
11.1.3.Genetic Testing |
11.1.4.Cognitive Assessment Tests |
11.2. Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Triage |
11.2.2.Diagnosis |
11.2.3.Screening |
11.3. End User Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.Hospital |
11.3.2.Diagnostic Laboratories |
11.3.3.Academic and Research Institutes |
11.4. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.4.1.China |
11.4.2.India |
11.4.3.Australia and New Zealand (ANZ) |
11.4.4.Japan |
11.4.5.Rest of APAC |
12.Middle East and Africa (MEA) Alzheimer’s Disease Diagnostics Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
12.1. Diagnostic Technique Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.Biomarkers |
12.1.2.Imaging Techniques |
12.1.3.Genetic Testing |
12.1.4.Cognitive Assessment Tests |
12.2. Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.Triage |
12.2.2.Diagnosis |
12.2.3.Screening |
12.3. End User Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Hospital |
12.3.2.Diagnostic Laboratories |
12.3.3.Academic and Research Institutes |
12.4. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.4.1.GCC Countries |
12.4.2.South Africa |
12.4.3.Rest of MEA |
13.Latin America Alzheimer’s Disease Diagnostics Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
13.1. Diagnostic Technique Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.1.1.Biomarkers |
13.1.2.Imaging Techniques |
13.1.3.Genetic Testing |
13.1.4.Cognitive Assessment Tests |
13.2. Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.2.1.Triage |
13.2.2.Diagnosis |
13.2.3.Screening |
13.3. End User Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.3.1.Hospital |
13.3.2.Diagnostic Laboratories |
13.3.3.Academic and Research Institutes |
13.4. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.4.1.Brazil |
13.4.2.Mexico |
13.4.3.Rest of LA |
14. Competition Landscape |
14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
14.2.1.Quest Diagnostics |
14.2.2.Labcorp |
14.2.3.C2N Diagnostics |
14.2.4.Fujirebio |
14.2.5.Hoffmann-La Roche |
14.2.6.Quanterix |
14.2.7.Sysmex |
14.2.8.Lantheus |
14.2.9.Siemens Healthineers |
15. Research Methodology |
16. Appendix and Abbreviations |
Key Market Players